Almirall updates its strategic focus, shares in a competitive pharma sector
Veröffentlicht: 28.06.2026 um 11:36 Uhr, Redaktion AD HOC NEWS, Redaktionelle Verantwortung: Rafael Müller (Chefredaktion)
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 11:36.
Almirall (ES0157097017) continues to position itself as a focused dermatology and specialty pharma player in Europe. The company competes with regional peers such as Sanofi and Novartis on prescription treatments, particularly in markets covered by EU regulators and national health systems.
Dermatology-centered strategy
Almirall presents itself as a global biopharmaceutical group with a clear focus on medical dermatology and related therapeutic areas. The group emphasizes innovation in inflammatory skin diseases and aesthetic dermatology as key growth drivers, supported by its R&D and licensing activities.
The company highlights autoimmune and inflammatory indications, including psoriasis and atopic dermatitis, as core targets for its pipeline and partner programs. Its strategy includes balancing proprietary R&D with in-licensing agreements and co-development deals that can accelerate market access in Europe and other regions.
Position among European peers
In its European home markets Almirall competes with larger pharmaceutical groups such as Sanofi and Novartis in prescription dermatology and immunology segments. The company aims to differentiate through focused expertise and a portfolio centered on dermatology rather than broad primary-care indications.
Compared with diversified peers, Almirall’s revenue base is more concentrated in dermatology and select specialty areas. That concentration increases exposure to reimbursement decisions and clinical guideline changes in those indications, but also allows management to allocate capital more tightly around a defined therapeutic niche.
Background and price data on Almirall
Further corporate releases, historical figures and price charts provide additional context on the Almirall shares and their long-term performance.
The product behind the stock
One of Almirall’s representative products is the psoriasis treatment Ilumetri (tildrakizumab), used for moderate-to-severe plaque psoriasis in adult patients in several European markets. The product illustrates the company’s focus on biologic therapies for chronic inflammatory skin diseases in its dermatology franchise.
Where the stock trades today
Almirall shares (ES0157097017) trade on the Bolsa de Madrid; a live-verifiable price for 2026-06-28, 11:36 in euros is not available in the sources used, so only the listing venue is reported.
Key data on the Almirall shares
- Company: Almirall S.A.
- ISIN: ES0157097017
- WKN: not available
- Ticker: ALM
- Trading venue: Bolsa de Madrid
- Price (as of 2026-06-28, 11:36): not available in the verified sources
- Market cap: not available in the verified sources
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: not clearly documented in the checked sources
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
